TUDRIQEV Prescriptions Start; Nautilus Opens Voyager Access

The Tip Desk · October 28, 2026 · 2 min read

Replimune reported early-October commercial availability of TUDRIQEV with institutional formulary and prescription activity, while Nautilus Biotechnology launched an Early Access Program for the Nautilus Voyager platform.

Replimune Group, Inc. (REPL), said TUDRIQEV became commercially available in early October 2026 and that, as of October 23, 2026, more than 15 institutions had written one or more prescriptions and started treating patients. About 20 melanoma institutions had placed the product on formulary since commercial launch.

The company said it had engaged with more than 70 percent of its 200 predefined priority accounts to establish workflows and enable efficient adoption and handling of TUDRIQEV. TUDRIQEV is approved under accelerated approval, in combination with nivolumab, for adults with unresectable advanced cutaneous melanoma who experienced disease progression on an anti-PD-1 antibody-based regimen; continued approval may be contingent on verification of clinical benefit in confirmatory trials.

Replimune said multiple payer policies from major national and regional payers covering TUDRIQEV according to its label, including retreatment if clinically appropriate, had been published since commercial launch and represented a majority of commercially covered lives. Medicare coverage had been established, and TUDRIQEV had been listed in the NCCN Clinical Practice Guidelines in Oncology as a category 2A. The company also established ReplimuneConnect Plus, a patient support program for enrolled TUDRIQEV patients.

Nautilus Biotechnology, Inc. (NAUT), said it announced the launch of its Iterative Mapping Early Access Program, starting with a target-specific service through which it performs analysis and profiling of samples at its facility and shares data and analysis via a cloud platform to enable initial customer access to the Nautilus Voyager platform. The company said development efforts for its broadscale assay had not advanced sufficiently to support general availability of that assay in 2027 to target specifications, and that it planned to reallocate resources from the broadscale effort to accelerate proteoform application development.

At the time of first commercial shipments, Nautilus said it expected general availability to include the Voyager instrument, a Tau Proteoforms assay, an AKT1 Proteoforms assay, and an additional oncology proteoforms assay, and that it expected to concurrently enable a broader diversity of sample types, including blood. It said it intended to commercialize the Nautilus Voyager platform through a direct sales channel in the United States and through both direct and distributor sales channels in regions outside the United States.